Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Evaxion Biotech Announces Q4 and Full-Year 2020 Financial Results and Provides Business Update
Evaxion BiotechApril 6, 2021 GMT
Successfully completed initial public offering on U.S. Nasdaq in February 2021, raising gross proceeds of $30 million
Clinical development on track with dosing of first patient in Phase 1/2a melanoma trial of cancer vaccine EVX-02 Cash reserves of $5.8 million at December 31, 2020 plus funds from IPO provide funding for at least 12 months from the date of completion of the IPO
COPENHAGEN, Denmark, April 06, 2021 (GLOBE NEWSWIRE) Evaxion Biotech A/S (Nasdaq: EVAX), a clinical-stage biotechnology company specializing in the development of AI-driven immunotherapies to improve the lives of patients with cancer and infectious diseases, announced today the fourth quarter and full year 2020 financial results and provided an operational update.
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
AB Science announces the signing of an exclusive licensing agreement with the University of .
AB ScienceApril 6, 2021 GMT
PRESS RELEASE
AB SCIENCE ANNOUNCES COLLABORATION WITH THE UNIVERSITY OF CHICAGO TO CONDUCT RESEARCH FOR THE PREVENTION AND TREATMENT OF COVID-19 WITH MASITINIB AND OTHER AB SCIENCE PROPRIETARY DRUGS
Paris, April 6 2021, 8am CET
AB Science SA (Euronext - FR0010557264 - AB), together with the University of Chicago, to
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Yumanity Therapeutics Announces Study Demonstrating In Vivo Efficacy of YTX-7739 in a .
Yumanity Therapeutics IncApril 6, 2021 GMT
YTX-7739 demonstrates efficacy, including increased median overall survival, both as a single agent and in combination with temozolomide, the standard-of-care for GBM
Shared therapeutic target with Parkinson’s disease expands potential utility of
YTX-7739 to non-neurodegenerative diseases
SNO/NCI Joint Symposium: Targeting CNS Tumor Metabolism
BOSTON, April 06, 2021 (GLOBE NEWSWIRE) Yumanity Therapeutics (NASDAQ: YMTX), a biopharmaceutical company focused on the development of innovative, disease-modifying therapies for neurodegenerative diseases, today announced results of a study that demonstrate
Press release content from Business Wire. The AP news staff was not involved in its creation.
Moderna Provides Storage Update & Announces the U.S. FDA Authorizes Up To 15-Doses Per Vial of its COVID-19 Vaccine
April 2, 2021 GMT
CAMBRIDGE, Mass. (BUSINESS WIRE) Apr 1, 2021
Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that based on submitted stability data, the U.S. Food and Drug Administration (FDA) has authorized the Moderna COVID-19 Vaccine to be kept at room temperature conditions once removed from the refrigerator for administration for 24 hours, an increase from the previous 12 hours. Additionally, a punctured vial is now useable for up to 12 hours, an increase from the previous 6 hours. These new guidelines are reflected in an updated Emergency Use Authorization (EUA) label. The Moderna COVID-19 Vaccine is ready for use and does not need to be diluted.
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
CytoDyn Files New Protocol with U.S. FDA for 4 Doses of Leronlimab for Critically Ill COVID-19 .
CytoDyn Inc.April 1, 2021 GMT
Trial commencement will be expedited by enrolling patients in Brazil, U.K., and Canada while immediate EUA requests are pursued in multiple countries
VANCOUVER, Washington, April 01, 2021 (GLOBE NEWSWIRE) CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company”), a late-stage biotechnology company developing Vyrologix™ (leronlimab-PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced today that after several weeks of discussions with the U.S. Food and Drug Administration (“FDA”) and analysis of CD12 trial data, and in particular the 82% survival results over placebo after two weeks of leronlimab treatment, with statistically significant p-value of 0.0233, the Company has filed a new protocol to extend tre